Gufic Biosciences Limited (GUFICBIO.BO)
- Previous Close
380.45 - Open
378.95 - Bid 376.70 x --
- Ask 380.55 x --
- Day's Range
378.10 - 388.10 - 52 Week Range
278.00 - 501.10 - Volume
4,097 - Avg. Volume
5,788 - Market Cap (intraday)
38.161B - Beta (5Y Monthly) 0.51
- PE Ratio (TTM)
46.52 - EPS (TTM)
8.18 - Earnings Date May 27, 2025 - May 31, 2025
- Forward Dividend & Yield 0.10 (0.03%)
- Ex-Dividend Date Sep 18, 2024
- 1y Target Est
--
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs) segments. In addition, the company offers criti care, criticare life, ferticare, and spark pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. It supplies its products to hospital chains and medical facilities. The company was founded in 1970 and is based in Mumbai, India.
www.gufic.com1,491
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: GUFICBIO.BO
View MorePerformance Overview: GUFICBIO.BO
Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GUFICBIO.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GUFICBIO.BO
View MoreValuation Measures
Market Cap
38.16B
Enterprise Value
40.92B
Trailing P/E
46.58
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
6.64
Enterprise Value/Revenue
5.29
Enterprise Value/EBITDA
28.06
Financial Highlights
Profitability and Income Statement
Profit Margin
10.12%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
8.1B
Net Income Avi to Common (ttm)
819.76M
Diluted EPS (ttm)
8.18
Balance Sheet and Cash Flow
Total Cash (mrq)
193.96M
Total Debt/Equity (mrq)
51.54%
Levered Free Cash Flow (ttm)
--